Cell phone screen sampling can detect viruses, and the cause of thrombosis caused by AstraZeneca vaccine was discovered. New crown research progresses in a week

Mobile phone screen sampling can detect new coronavirus

Mobile phone screen sampling can detect new coronavirus

Source: eLife

Source: eLife Source: eLife

Recently, in a work published in eLife, the research team developed a mobile phone screen detection (PoST) method that can use samples collected from mobile phone screens to detect the new coronavirus
.

People who tested positive by routine nasal swabs also tested positive from mobile phone screens, and the virus was detected on mobile phones of 81% to 100% of highly infectious people

The PoST method can not only make large-scale testing of the new crown easier, but also can be used to contain the outbreak of unknown viruses and avoid future pandemics
.

Single-dose adenovirus vaccine shows neutralizing activity against various new crown variants such as Delta

Single-dose adenovirus vaccine shows neutralizing activity against various new crown variants such as Delta

Source: bioRxiv

Source: bioRxiv Source: bioRxiv

On July 1, Johnson & Johnson announced that its single-dose new crown vaccine Ad26.
COV2.
S showed strong and lasting activity against the rapidly spreading Delta variant and other widely spreading new crown virus variants
.

Data from another study showed that the immune response triggered by the vaccine can last at least 8 months

Ad26.
COV2.
S is a new coronavirus vaccine that uses adenovirus serotype 26 (Ad26) vector to express the new coronavirus spike protein.
It only needs one shot to provide protection
.

The emergency use authorization has been granted by the US FDA

Infection with the new crown can damage blood cells

Infection with the new crown can damage blood cells

Source: Biophysical Journal

Source: Biophysical Journal Source: Biophysical Journal

In a work published in the Biophysical Journal on July 2, researchers used a cell real-time deformation measuring instrument and found that the new coronavirus can significantly change the size and hardness of red blood cells and white blood cells in the human body.
It can take as long as several months
.

The study also found that the oxygen supply capacity of red blood cells in patients with new coronary pneumonia is also impaired during the infection, and the patients' lymphocytes have also become significantly softer
.

In addition, 7 months after infection, the patient's neutrophils still had significant changes

This finding may help explain why some symptoms will persist for a long time in patients with new coronary pneumonia
.

Key mutations in the cross-species transmission of the new coronavirus have been discovered

Key mutations in the cross-species transmission of the new coronavirus have been discovered

Source: Cell

Source: Cell Source: Cell

On July 6, a study published in Cell pointed out that the T372A single-mutation new coronavirus adapts to the key mutation of the human host
.

By analyzing 182,000 SARS-CoV-2 genomes, the researchers discovered an important base mutation tag (A1114G).

This mutation is present in all human SARS-CoV-2 sequences, but not in related bat and pangolin coronaviruses
.

WTO includes interleukin-6 receptor antagonist in new crown treatment plan

WTO includes interleukin-6 receptor antagonist in new crown treatment plan

On July 6, the WHO updated the guidelines for the care of patients with COVID-19, including interleukin-6 receptor antagonists in the list of available drugs.
This is a class of drugs that have a life-saving effect on critically ill patients with COVID-19 and is used in combination with corticosteroids.
The effect is particularly remarkable
.

Compared with standard therapy, the use of interleukin-6 receptor antagonists in critically ill patients with new coronary disease can reduce the mortality rate by 13%, and the number of deaths per 1,000 critically ill patients can be reduced by 28; the chance of mechanical ventilation in critically ill patients is reduced By 28%, the number of critically ill patients requiring mechanical ventilation can be reduced by 23
.

The small RNA of the new coronavirus may predict the occurrence of severe illness

The small RNA of the new coronavirus may predict the occurrence of severe illness

Source: Cell Discovery

Source: Cell Discovery Source: Cell Discovery

On July 6, in a paper published in Cell Discovery, researchers identified a microRNA-like small RNA (milRNA) encoded by the new coronavirus in the serum of patients with new coronavirus.
milRNA only exists in the sera of severely ill patients, and is not detected in the sera of mild patients and healthy people
.

The data shows that the accuracy of this marker for predicting severe illness is as high as 97.

In clinical treatment, the monitoring of this milRNA will hopefully help doctors to determine the course of the disease of patients with new coronary disease in advance, and to closely monitor and treat patients who are about to enter the severe phase, thereby reducing patient mortality
.

Over 70% of recovered patients with COVID-19 remain positive for antibodies within one year after infection

Over 70% of recovered patients with COVID-19 remain positive for antibodies within one year after infection

Source: Nature Communications

Source: Nature Communications Source: Nature Communications

On July 6, a study published in Nature Communications showed that more than 70% of patients recovered from COVID-19 had positive antibody levels within 12 months after infection, and their antibody titers remained positive.
It stabilized at the 9th month (a decrease of about 64% from the beginning of the infection)
.

After stabilization, the antibody titer can be maintained until the 12th month without showing a significant downward trend

The study also found that in the first to two months after infection with the new crown, the antibody titers in men were higher than in women, but there was no significant difference between the 6th and 7th months and the 11th and 12th months
.

The study included 869 patients who recovered from natural infections in Wuhan, and a total of 1782 plasma samples were collected and analyzed
.

Antibodies of AstraZeneca vaccine bind to clotting proteins or can cause blood clots

Antibodies of AstraZeneca vaccine bind to clotting proteins or can cause blood clots

Source: Nature

Source: Nature Source: Nature

In a work published in Nature on July 7, researchers analyzed the serum of 5 immune thrombotic thrombocytopenia patients (average age 44) who had received a dose of AstraZeneca vaccine.
It was found that the antibodies in their bodies would bind to a protein involved in blood coagulation, and the binding site and the site where the anticoagulant drug heparin binds to the protein were the same
.

The two combine to form immune complexes, which then activate platelets through another receptor on the platelet surface, which may cause blood clotting, leading to thrombocytopenia and thrombosis
.

Kexing vaccine real-world research data released

Kexing vaccine real-world research data released

Source: NEJM

Source: NEJM Source: NEJM

On July 7, a paper published in the New England Journal of Medicine (NEJM) announced the real-world study of the Chilean mass vaccination of the CoronaVac vaccine, the CoronaVac vaccine
.

The results of the study showed that for people who received two doses of vaccine, the estimated protective effect of preventing disease was 65.
9%, the protective effect of preventing hospitalization was 87.
5%, the protective effect of preventing admission to intensive care unit was 90.
3%, and the protective effect of preventing death was 90.
3%.
The protective effect is 86.
3%
.

This is the first time that NEJM has published the results of a large-sample clinical study of China's new crown virus vaccine, marking that the real-world effectiveness data of China's new crown virus vaccine has been recognized by international peers
.

A new target for the treatment of new crowns has been discovered

A new target for the treatment of new crowns has been discovered

Source: Nature Cell Biology

Source: Nature Cell Biology Source: Nature Cell Biology

On July 8, a study published in Nature Cell Biology revealed the relationship between nucleocapsid protein (SARS2-NP)-mediated innate immune escape, protein post-translational modification, and mutation Mechanism, SARS2-NP protein has the ability to undergo liquid-liquid phase separation, and the dimerization domain in it is very critical for its phase separation activity
.

The researchers found that the NP protein contains a highly acetylated site, and the mimic acetylation mutation at this site will destroy the liquid-liquid phase separation ability of the SARS2-NP protein, proving that the phase separation activity of the SARS2-NP protein can be used as a new crown Possible therapeutic targets after virus infection provide new possibilities for related drug development
.

50,000 genetic data reveal sites related to new crown susceptibility and severity

50,000 genetic data reveal sites related to new crown susceptibility and severity

Source: Nature

Source: Nature Source: Nature

On July 8, a study published in Nature revealed 13 new genomic regions related to susceptibility to new crowns and disease severity
.

The researchers compiled 46 groups of studies, covering 19 countries in East Asia, South Asia, Africa, America, Europe, Africa, the Middle East and other regions, including people of different ancestry, involving nearly 50,000 new crown patients, and 200 as a control.
Ten thousand people
.

According to the severity, three genome-wide association meta-analyses were carried out, and 4 sites related to the susceptibility of the new crown virus and 9 sites related to the severity of the new crown pneumonia were found

Leave a message here